Contemporary Sequencing in the Treatment of Prostate Cancer - Neal Shore, Alicia Morgans and Charles Ryan

Alicia Morgans, Charles Ryan, and Neal Shore discuss the clinical evidence and considerations in treating prostate cancer progression as patients fail first-line treatment in the nmCRPC and advance to metastatic castration-resistant prostate cancer (mCRPC).  They highlight the need to change the mechanism of action and the opportunities that each Sipuleucel-T, (Provenge®) an autologous cellular immunological agent and radium-223 dichloride (Xofigo®) a radioactive therapeutic agent offer in patients progressing to mCRPC.  These agents have each demonstrated improved overall survival while being tolerable and safe.  

Biographies:

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Charles J. Ryan, MD, The B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology, and Transplantation.

Neal Shore, MD, FACS is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association.